



PRESS RELEASE

Carmat's Scientific Advisory Board meets to prepare the company's clinical trials through to 2011

Professor Alain Carpentier chairs the meeting at EACTS 2010 in Geneva

Paris, September 15, 2010

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, today announced that its Scientific Advisory Board had met on September 12 at the venue of the 24th Annual Meeting of the European Association for Cardiothoracic Surgery (EACTS) in Geneva (Switzerland). The Scientific Advisory Board (chaired by Professor Alain Carpentier) discussed the preparation of Carmat's clinical trials through to the end of 2011.

"I was delighted to have chaired the Scientific Advisory Board meeting. The board members' expertise and experience generated highly fruitful discussions concerning our exceptional biomedical project and the scheduled clinical trials in man", commented Professor Alain Carpentier.

Carmat CEO Marcello Convitì added: *"Our Scientific Advisory Board is playing a key role in the preparation and implementation of these clinical trials and we are delighted with the progress discussed during this prestigious European conference".*

[In July, Carmat successfully listed on the Alternext market of NYSE Euronext](#), with a view to performing the first implantation of its total artificial heart in a patient in 2011 and commercializing the device by 2013.

The members of Carmat's Scientific Advisory Board (in alphabetical order)

- **Professor Alain Carpentier:** Carmat's Scientific Director and Emeritus Professor at Pierre, Marie Curie University (Paris, France) and Chairman of the French Academy of Science
- **Professor Gilles Dreyfus:** Thoracic and cardiovascular surgeon and Chief Medical officer of the Cardio-thoracic Centre of Monaco
- **Professor Daniel Dureau:** Head of the Nantes Thorax institute and Professor of thoracic and cardiovascular surgery at the Nantes University Hospital (France)
- **Dr Edoardo Gronda:** Director of the Clinical Cardiology and Heart Failure Therapy Division of the Humanitas Clinical Institute in Milan (Italy)
- **Professor Günther Laufer:** Director of the Division of Cardiothoracic Surgery at the Medical University of Vienna (Austria)
- **Professor Paul Mohacsi:** Director of the Clinic for Heart Failure and Transplantation at the Swiss Cardiovascular Center in Bern (Switzerland)
- **Professor Friedrich Mohr:** Medical Director of the Heart Surgery Clinic at the University of Leipzig (Germany) and Professor of Cardiovascular Surgery at Göttingen University (Germany)
- **Dr Rémy Nottin :** General Secretary of French Society thoracic and head of cardiovascular surgery department at Marie Lannelongue Hospital, Le Plessy Robinson, France
- **Professor Mark Slaughter:** Head of the Division of Thoracic and Cardiovascular Surgery at the University of Louisville (Kentucky, USA)

About Carmat

CARMAT, the world's most advanced total artificial heart project

The only credible response for all cases of end-stage heart failure, which is a real public health issue: CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

The result of the combination of two types of unique expertise: the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

Imitating the natural heart: given its size, its weight, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

A project leader acknowledged at a European level: with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by OSEO; a total of €33 million.

Substantial involvement of prestigious shareholders: Truffle Capital, the leading European venture capital firm, EADS and the Fondation Alain Carpentier.

For more information: www.carmatsas.com

CARMAT

Marcello Conviti
CEO

Patrick Coulombier
COO

Tél. : 01 39 45 54 50

investisseurs@carmatsas.com

ALIZE RP – Corporate Communication & Press Relations

Caroline Carmagnol
Tel.: +33 (0)6 64 18 99 59

caroline@alizerp.com

Juliette Vandebroucq

Tel.: +33 (0)1 41 68 86 41

juliette@alizerp.com

ALCAR
LISTED
NYSE
ALTERNEXT

Name: **CARMAT**
ISIN code: **FR0010907956**
Ticker: **ALCAR**